IL6 and osteoporosis: The overactivated IL-6-STAT3 pathway inhibits β-catenin activity, and anti-IL-6 neutralizing antibodies rescue the osteoporotic phenotype in rodents (44), providing a potential therapeutic target for osteoporosis.